Agenus IncNASDAQ:AGEN
- LAST PRICE3.3300
- TODAY'S CHANGE (%)-0.1600 (-4.5845%)
- Bid / Lots3.3200/ 5
- Ask / Lots3.3300/ 1
- Open / Previous Close3.5200 / 3.4900
- Day Range
- 52 Week Range
- Volume148,109
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGEN |
|---|---|---|
| 09:32 ET | 11710 | 3.49 |
| 09:33 ET | 4012 | 3.485 |
| 09:35 ET | 5596 | 3.49 |
| 09:37 ET | 800 | 3.516 |
| 09:39 ET | 1060 | 3.49 |
| 09:42 ET | 4695 | 3.4292 |
| 09:44 ET | 4473 | 3.41 |
| 09:46 ET | 841 | 3.41 |
| 09:48 ET | 2943 | 3.39 |
| 09:50 ET | 100 | 3.395 |
| 09:51 ET | 1905 | 3.38 |
| 09:53 ET | 5979 | 3.38 |
| 09:55 ET | 11678 | 3.35 |
| 09:57 ET | 3028 | 3.33 |
| 10:00 ET | 4500 | 3.326 |
| 10:02 ET | 1152 | 3.31 |
| 10:04 ET | 5970 | 3.34 |
| 10:06 ET | 1793 | 3.36 |
| 10:08 ET | 800 | 3.32 |
| 10:09 ET | 973 | 3.32 |
| 10:11 ET | 300 | 3.3 |
| 10:13 ET | 3136 | 3.33 |
| 10:15 ET | 200 | 3.33 |
| 10:18 ET | 100 | 3.33 |
| 10:20 ET | 4544 | 3.3 |
| 10:22 ET | 2850 | 3.36 |
| 10:24 ET | 300 | 3.352 |
| 10:26 ET | 1400 | 3.37 |
| 10:27 ET | 147 | 3.3688 |
| 10:31 ET | 100 | 3.38 |
| 10:33 ET | 1902 | 3.395 |
| 10:36 ET | 895 | 3.36 |
| 10:38 ET | 3200 | 3.35 |
| 10:40 ET | 798 | 3.36 |
| 10:44 ET | 950 | 3.3699 |
| 10:45 ET | 2832 | 3.38 |
| 10:47 ET | 464 | 3.3707 |
| 10:51 ET | 100 | 3.38 |
| 10:54 ET | 600 | 3.37 |
| 10:58 ET | 200 | 3.38 |
| 11:00 ET | 3657 | 3.385 |
| 11:02 ET | 6952 | 3.35 |
| 11:03 ET | 3735 | 3.3539 |
| 11:05 ET | 200 | 3.35 |
| 11:09 ET | 6358 | 3.335 |
| 11:18 ET | 3040 | 3.33 |
Today
Nov 27, 2024
*DJ Agenus Secures $22M Mortgage and Announces Strategic Operational Realignment, from 8:15AM ET on Wednesday Nov 27, 2024 by Dow Jones
8:15AM ET on Wednesday Nov 27, 2024 by Dow JonesAgenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment, from 8:15AM ET on Wednesday Nov 27, 2024 by Dow Jones
8:15AM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 12, 2024
DJ Agenus Price Target Cut to $7.00/Share From $8.00 by HC Wainwright & Co., from 11:13AM ET on Tuesday Nov 12, 2024 by Dow Jones
11:13AM ET on Tuesday Nov 12, 2024 by Dow JonesAgenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agenus Inc | 81.9M | -0.3x | --- |
Karyopharm Therapeutics Inc | 109.8M | -1.1x | --- |
FibroGen Inc | 39.1M | -0.3x | --- |
Sutro Biopharma Inc | 221.8M | -1.6x | --- |
Seres Therapeutics Inc | 149.7M | -0.9x | --- |
Heron Therapeutics Inc | 176.4M | -6.5x | --- |
Company Information
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Contact Information
- Headquarters
- 3 Forbes RdLEXINGTON, MA, United States 02421-7305
- Phone
- 781-674-4400
- Fax
- 781-674-4200
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Garo Armen
- Vice President - Finance
- Christine Klaskin
- Chief Medical Officer
- Steven O'Day
- Head of Regulatory
- Eric Olson
- Lead Independent Director
- Timothy Wright
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $81.9M |
|---|---|
Revenue (TTM) | $160.4M |
Shares Outstanding | 23.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-11.06 |
Book Value | $-8.13 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 0.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61.57% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
